Ref9C8
Med. Sci
Res., 1991’ 19, 827-828
Pharacokinetic
studies of silybin-phosphatidylcholine complex (Siliphos®)
in liver cirrhosis after multiple doses
Rocco
Orlando, Annalisa Fragasso, Mario Lampertico1 and Carlo Marena1
Institute
of Internal Medicine, University of Padua, Italy, and 1Medical
Department, Inverni della Beffa, Milan, Italy
Journal
not found on Medline
Introduction:
Silybin is the main active component of silymarin, a standardized
extract from the seeds of Silybum marianum Gaertn. (Siliphos®)
is a complex between silybin and soybean phosphatidylcholine,
which exerts protective effects against hepatic lesions induced
by toxic agents such as alcohol and phalloidin (1,2).
The data
obtained in cirrhotic patients after multiple doses of IdB
1016 (Siliphos®) did not show significant differences
from those reported after a single dose. They clearly show
that the drug does not accumulate in cirrhotic patients.
Furthermore
the results indicate no significant difference from healthy
control subjects.
It is
therefore posited that this substance can be safely employed
in long-term treatment of chronic liver patients.
1. Ferenci,
P., Dragosics, B., Frank, H. et al. 1985. Abstr. J. Hepatol.,
1, S229
2. Salmi,
H.A. and Sarna, S. 1982, Scand. J. Gastroenterol., 17, 517-521
Ref9C8
|
